نتایج جستجو برای: rosuvastatin

تعداد نتایج: 1991  

2013
Francesco Londrino Tito Zattera Valeria Falqui Valentina Corbani Marco Cavallini Teseo Stefanini Nadia Chiappini Michela Ardini Valentina Martina Giuseppe Rombolà

We report a case of acute interstitial nephritis (AIN), most likely induced by rosuvastatin, in an 83-year-old male patient. The patient underwent angioplasty of the left internal carotid artery, after which he began a regimen of rosuvastatin (20 mg/day). After 3 weeks the patient was admitted to our unit for acute renal failure with mild proteinuria with negligible urinary sediment. A left kid...

Journal: :International journal of molecular medicine 2011
Yukinori Tamura Toshinori Murayama Manabu Minami Masayuki Yokode Hidenori Arai

Recent studies suggest a potential benefit of the lipid-lowering medication in the treatment of chronic kidney disease (CKD) such as diabetic nephropathy. Although statins have been widely used to lower serum cholesterol levels, the effect of these drugs on diabetic nephropathy has not been fully elucidated. In the present study, therefore, we addressed the role of different kinds of statins on...

2017
Kyoung Min Kim Kyong Yeun Jung Han Mi Yun Seo Young Lee Tae Jung Oh Hak Chul Jang Soo Lim

BACKGROUND The cardiovascular benefits of statins have been proven, but their effect on circulation in small vessels has not been examined fully. We investigated the effect of 20 mg rosuvastatin on biomarkers, including paraoxonase-1 (PON-1) and asymmetric dimethylarginine (ADMA), and on microvascular reactivity. METHOD We enrolled 20 dyslipidemic patients with type 2 diabetes and 20 age- and...

Journal: :The American journal of cardiology 2016
Björn W Karlson Michael K Palmer Stephen J Nicholls Pia Lundman Philip J Barter

Elevated triglyceride (TG) levels are associated with increased cardiovascular disease risk. In patients with mild-to-moderate hypertriglyceridemia, defined by the European Atherosclerosis Society Consensus Panel as a TG level of 177 to 885 mg/dl (2.0 to 10.0 mmol/L), low-density lipoprotein cholesterol (LDL-C) reduction remains the primary treatment goal. Using data from the indiVidual patient...

Journal: :European heart journal 2012
Lars Gullestad Thor Ueland John Kjekshus Ståle H Nymo Johannes Hulthe Pieter Muntendam Aram Adourian Michael Böhm Dirk J van Veldhuisen Michel Komajda John G F Cleland John Wikstrand John J V McMurray Pål Aukrust

AIMS To investigate whether plasma galectin-3, a mediator of fibrogenesis, can identify patients with chronic heart failure (HF) for whom statins are effective. METHODS AND RESULTS Patients with ischaemic systolic HF enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) were randomly assigned to 10 mg/day of rosuvastatin or placebo. Galectin-3 was measured in p...

Journal: :The New England journal of medicine 2007
John Kjekshus Eduard Apetrei Vivencio Barrios Michael Böhm John G F Cleland Jan H Cornel Peter Dunselman Cândida Fonseca Assen Goudev Peer Grande Lars Gullestad Ake Hjalmarson Jaromir Hradec András Jánosi Gabriel Kamenský Michel Komajda Jerzy Korewicki Timo Kuusi François Mach Vyacheslav Mareev John J V McMurray Naresh Ranjith Maria Schaufelberger Johan Vanhaecke Dirk J van Veldhuisen Finn Waagstein Hans Wedel John Wikstrand

BACKGROUND Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of ro...

2013
Miao Hu Brian Tomlinson

Correspondence: Brian Tomlinson Department of Medicine and Therapeutics, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, Hong Kong Tel/Fax +852 2632 3139 Email [email protected] Abstract: Rosuvastatin is one of the most potent statins available for reducing circulating lowdensity lipoprotein cholesterol (LDL-C) levels, which enables more high-risk patients to achieve their lipid...

Journal: :Lancet 2008
Luigi Tavazzi Aldo P Maggioni Roberto Marchioli Simona Barlera Maria Grazia Franzosi Roberto Latini Donata Lucci Gian Luigi Nicolosi Maurizio Porcu Gianni Tognoni

BACKGROUND Large observational studies, small prospective studies and post-hoc analyses of randomised clinical trials have suggested that statins could be beneficial in patients with chronic heart failure. However, previous studies have been methodologically weak. We investigated the efficacy and safety of the statin rosuvastatin in patients with heart failure. METHODS We undertook a randomis...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2012
Jibin Li Ying Wang Wei Zhang Yuehua Huang Kristin Hein Ismael J Hidalgo

Membrane transporters can play a clinically important role in drug absorption and disposition; Caco-2 and Madin-Darby canine kidney (MDCK) cells are the most widely used in vitro models for studying the functions of these transporters and associated drug interactions. Transport studies using these cell models are mostly focused on apical transporters, whereas basolateral drug transport processe...

2012
Andrew van Herick C Andy Schuetz Peter Alperin Michael F Bullano Sanjeev Balu Sanjay Gandhi

PURPOSE Many patients treated for dyslipidemia do not achieve recommended cholesterol goals despite the widespread availability of effective statins. Pharmaceutical claims show a strong tendency for patients to remain on their initially assigned treatment. With computer simulations, the impact of initial statin treatment decisions on medium- and long-term cardiovascular outcomes were examined. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید